NFA
VRDN icon

Nationwide Fund Advisors’s Viridian Therapeutics VRDN Stock Holding History

Nationwide Fund Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-469
Closed -$64K – 2048
2017
Q3 		$64K Buy
469
+35
+8% +$5.89K ﹤0.01% 3012
2017
Q2 		$84K Buy
+434
New +$73.3K ﹤0.01% 2965

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

Nationwide Fund Advisors's VRDN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Viridian Therapeutics (VRDN) in Q4 2017, closing a stake of 469 shares — an estimated $64K sold.

Nationwide Fund Advisors first reported a position in VRDN in Q2 2017 and held it in 2 quarters. The position peaked at $84K in Q2 2017. 51 funds tracked by Wall St. Rank hold VRDN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Viridian Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 469 Viridian Therapeutics shares in Q4 2017, an estimated $64K.
  • Nationwide Fund Advisors first reported a position in Viridian Therapeutics in Q2 2017 and held it in 2 quarters.
  • Nationwide Fund Advisors's Viridian Therapeutics position peaked at $84K in Q2 2017.
  • 51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.